Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion LUNG 2 first-line zongertinib vs standard of care in HER2-mutated NSCLC
jRCT2071230098Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of zongertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Progression-free survival (PFS). Started Jan 2024; status: active, not recruiting.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2071230098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230098.